CVS Health and Pfizer are two of the most widely held healthcare stocks in the U.S., yet they compete in very different parts of the industry. CVS operates a vertically integrated model spanning health insurance (Aetna), pharmacy benefit management (Caremark), and retail pharmacies, while PFE is a pure-play biopharmaceutical company built on patented medicines and vaccines. This comparison is relevant for investors weighing a diversified health-services recovery story against a pharmaceutical turnaround driven by new product launches. Understanding their relative performance, growth drivers, and risk profiles can help both long-term investors and active traders assess which name is better positioned in the current market environment. I also checked this using Tickeron’s AI Trend Prediction Engine to compare momentum signals across the sector.
CVS is a diversified health solutions company whose core segments are Health Care Benefits (primarily the Aetna insurance business), Health Services (led by the Caremark pharmacy benefit manager, or PBM), and Pharmacy & Consumer Wellness. In recent weeks, the company has reported better-than-expected earnings, driven mainly by an improving medical benefit ratio (the share of premiums paid out for medical claims) in its insurance business. Management has raised full-year guidance multiple times, a signal that its multi-year margin-recovery plan is progressing faster than anticipated.
The most significant recent development has been the announcement of a plan to split CVS into two publicly traded companies — one retaining Aetna and Caremark, the other holding roughly 9,000 retail pharmacies — with completion targeted for the first half of 2028. The market reaction was mixed: shares initially fell sharply on uncertainty around the costs and financial structure of the separation, then partially recovered. Sentiment has been shaped by both the company's improving fundamentals and questions about whether the breakup will unlock value or create execution risk.
PFE is a global pharmaceutical company focused on oncology, vaccines, immunology, and internal medicine. The company is navigating a structural transition: revenue from its COVID-19 products (Comirnaty and Paxlovid) has declined sharply, while its "launched and acquired products" portfolio — including cancer drug Padcev, blood thinner Eliquis, and migraine treatment Nurtec — has been growing at a rapid pace. In its most recent quarter, Pfizer beat analyst estimates and raised full-year revenue and adjusted earnings guidance. From what I see, the technical picture has held up well here.
Recent market activity has been relatively favorable, with the stock outperforming the broader market and posting strong relative strength. However, the forward story carries meaningful risk: several blockbuster drugs face loss of exclusivity (patent expirations) between 2026 and 2030, creating a "patent cliff" that new products must offset. Pfizer has responded with substantial acquisitions and cost-reduction programs, and it continues to pay one of the highest dividend yields among large-cap pharmaceutical companies, which has supported investor interest despite flat top-line growth.
The two companies differ sharply in business model and risk profile. CVS is a low-margin, high-revenue health services and insurance conglomerate whose earnings depend heavily on medical cost management and pharmacy reimbursement dynamics. Its key catalysts are the Aetna margin recovery and the proposed company split. PFE is a higher-margin drug developer whose earnings hinge on patent-protected products, clinical pipeline outcomes, and the pace of new product adoption.
On momentum, Pfizer has shown greater trend consistency in recent months, with shares outperforming the S&P 500 and receiving strong relative strength ratings, whereas CVS has experienced choppier price action around its breakup announcement and showed broad capital outflows across investor classes. On income, Pfizer's dividend yield is roughly double CVS's, making it more attractive to income-oriented investors, though that yield reflects concerns about Pfizer's growth. In contrast, CVS trades at a lower earnings multiple and is generating substantial free cash flow, but it carries meaningful debt and faces regulatory scrutiny of its integrated model. Sector exposure also differs: CVS is more sensitive to healthcare policy and insurance utilization, while Pfizer is more exposed to patent expirations, drug pricing, and clinical trial outcomes. I reviewed relative strength metrics here with Tickeron’s AI Pattern Search Engine as well.
Based on observable factors such as trend consistency, relative momentum, dividend support, and recent guidance momentum, Tickeron's AI would currently favor PFE over CVS. Pfizer's steadier upward price trend, strong relative strength, and consistent earnings beats suggest a more stable technical and fundamental setup, even as its patent cliff remains a longer-term overhang. CVS's improving fundamentals are notable, but the uncertainty surrounding its planned separation and the choppier recent price action introduce more near-term variability. This verdict is probabilistic rather than definitive: the balance could shift if CVS provides clearer separation details or if Pfizer's pipeline or patent-expiration headwinds disappoint.
I often turn to Tickeron’s Trending AI Robots when comparing names like these two. The section highlights automated systems that have performed well in current conditions across thousands of tickers. It lets me quickly review different strategies, timeframes, and risk levels without building models from scratch. For investors looking at CVS and PFE, it offers a practical view of how quantitative approaches are positioned right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PFE saw its Momentum Indicator move below the 0 level on November 12, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned negative. In 57 of the 89 cases, the stock moved further down in the following days. The odds of a decline are at 64%.
The Moving Average Convergence Divergence Histogram (MACD) for PFE turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 24 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 56%.
PFE moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +0.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in 153 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
PFE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 94 of 185 cases where PFE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 51%.
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.966) is normal, around the industry mean (-1.421). P/E Ratio (38.169) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (13.137) is also within normal values, averaging (5.738). Dividend Yield (0.059) settles around the average of (0.038) among similar stocks. P/S Ratio (2.469) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of vaccines and injectable biologic medicines
Industry PharmaceuticalsMajor